| 1.25 0.01 (0.81%) | 12-05 10:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.65 | 1-year : | 1.89 |
| Resists | First : | 1.41 | Second : | 1.62 |
| Pivot price | 1.18  |
|||
| Supports | First : | 1.09 | Second : | 0.9 |
| MAs | MA(5) : | 1.2 |
MA(20) : | 1.21 |
| MA(100) : | 1.27  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62.9 |
D(3) : | 47.1 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 1.89 | Low : | 0.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OCGN ] has closed below upper band by 13.0%. Bollinger Bands are 56.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.26 - 1.26 | 1.26 - 1.27 |
| Low: | 1.18 - 1.19 | 1.19 - 1.19 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Wed, 12 Nov 2025
Ocugen (OCGN) Is Down 7.0% After Mixed Q3 Results and Gene Therapy Milestones – What's Changed - simplywall.st
Tue, 11 Nov 2025
Ocugen (OCGN) Sees Higher Revenue but Wider Losses Is Funding the Pipeline a Growing Challenge? - Yahoo Finance
Sun, 09 Nov 2025
Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. $OCGN - MarketBeat
Sun, 09 Nov 2025
Ocugen Inc (OCGN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Wed, 05 Nov 2025
Ocugen (NASDAQ: OCGN) 50% OCU410ST enrolled; EMA accepts single U.S. trial for MAA - Stock Titan
Wed, 29 Oct 2025
Ocugen (OCGN) Price Target Increased by 26.15% to 8.36 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 312 (M) |
| Held by Insiders | 3.0765e+008 (%) |
| Held by Institutions | 1.4 (%) |
| Shares Short | 58,100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.751e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 81.2 % |
| Return on Equity (ttm) | -63.7 % |
| Qtrly Rev. Growth | 5.37e+006 % |
| Gross Profit (p.s.) | 12.01 |
| Sales Per Share | -64.29 |
| EBITDA (p.s.) | -7.09534e+006 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 556.98 |
| Dividend | 0 |
| Forward Dividend | 5.909e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|